0001127602-18-033263.txt : 20181115
0001127602-18-033263.hdr.sgml : 20181115
20181115204003
ACCESSION NUMBER: 0001127602-18-033263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181114
FILED AS OF DATE: 20181115
DATE AS OF CHANGE: 20181115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Axon Steven
CENTRAL INDEX KEY: 0001720605
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 181188491
MAIL ADDRESS:
STREET 1: C/O APELLIS PHARMACEUTICALS, INC.
STREET 2: 6400 WESTWIND WAY, SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
BUSINESS PHONE: 502-241-4114
MAIL ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2018-11-14
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001720605
Axon Steven
C/O APELLIS PHARMACEUTICALS, INC
6400 WESTWIND WAY, SUITE A
CRESTWOOD
KY
40014
1
Chief Business Officer
Common Stock
2018-11-14
4
M
0
11500
2.59
A
50110
D
Stock Option (Right to Buy)
2.59
2018-11-14
4
M
0
11500
0
D
2027-05-17
Common Stock
11500
348389
D
This option was granted on May 18, 2017 and has vested as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.
This option was granted on May 18, 2017 and will vest as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.
/s/ David Watson, attorney-in-fact for Steven Axon
2018-11-15